Insider buying last 90 days
No open-market insider purchases were filed for RPRX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 16 close
Royalty Pharma presented at the UBS Global Biopharma Conference on 17 November and continues to draw analyst attention after Q3 royalty receipts rose 9% to $883 million, led by Tremfya, Voranigo, and Evrysdi, with Vertex now accounting for approximately 25% of royalty receipts as newer medicines reduce portfolio concentration. Filings this week also showed Eurizon Capital SGR S.p.A. and Alps Advisors Inc. trimming their positions in RPRX.
RPRX closed at $68.53, down 1.1%, with the close sitting above both the 50-day average of $61.61 and the 200-day average of $54.76, reflecting a supportive longer-term trend. The stock trades within 52-week range of $37.31 to $70.37, with one-year return of 72.5%. The GekkoIndex reads 45.8, placing it in the Neutral zone, while the price sits 21.9% above Gekko Fair Value of $56.22.
The next earnings date falls on 10 February 2027, 85 days out and beyond a typical 20-trading-day holding window; the prior quarter saw an EPS beat of $1.32 versus $1.27 estimated, with a reaction of -0.4%. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows, though one billionaire holder is recorded. Seasonality over the next 20 trading days has averaged -1.9% across 5 years, rising in 1 of them, a pattern worth noting alongside the six analyst firms currently rating the stock buy with a consensus target of $72.
Written by AI from the Nov 16, 2026 close and checked automatically against the figures on this page.
Royalty Pharma scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
Above 50 and 200-day
Close $68.53 is above the 50-day ($61.61) and 200-day ($54.76) averages, and the 50-day is above the 200-day.
See the chart45.8, Neutral
Reading 45.8 is in the Neutral zone.
See the GekkoIndex21.8% above
Price is 21.8% above Gekko Fair Value (more than 5% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 85 days
Next report Feb 10, 2027, 85 days away — outside a typical 20-trading-day hold.
See earnings−3.4% on average
From this point in the calendar, the next 20 trading days averaged −3.4% over 5 years, rising in 1 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Royalty Pharma closed at $68.53 on Nov 16, 2026, +72.5% over the past year, inside a 52-week range of $37.31 to $70.37.
Use the left and right arrow keys to read daily values.
Put RPRX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Royalty Pharma acquires royalty streams tied to biopharmaceutical products rather than developing drugs itself, and in doing so helps finance work across the biopharmaceutical industry in the United States. Its holdings cover rights to roughly 35 therapies already on the market along with around 20 candidates still in development, spanning areas such as rare disease, cancer, neuroscience, infectious disease, blood disorders, and diabetes.
Its business centers on purchasing these royalty interests, which links its earnings to the commercial performance of medicines developed and sold by other companies in the sector rather than to any products it makes or markets directly.
Royalty Pharma traces back to 1996 and operates out of New York, New York. Its shares are listed on the NASDAQ under the ticker RPRX.
Royalty Pharma’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 45.8, in the Neutral zone, up 3.4 points over five sessions.
Up 3.4 points over five sessions, from the Distribution zone.
Reading for Nov 16, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 24 | +1.5% | +5.4% | ||
| Accumulation | 157 | +0.2% | +3.1% | ||
| Neutral (current zone) | 451 | +0.8% | +2.2% | ||
| Distribution | 73 | +0.4% | +2.9% | ||
| Selling | 2 | Too few readings yet | |||
Average RPRX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Royalty Pharma trades 21.8% above Gekko Fair Value of $56.26, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Royalty Pharma shares are worth, recalculated every trading day.
$56.26
Gekko Fair Value, Nov 17, 2026
21.8% Overvalued
At the end of Aug 2026 the price was 32.9% above the estimate.
No open-market insider purchases were filed for Royalty Pharma, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for RPRX in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in RPRX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Royalty Pharma has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds RPRX.
Royalty Pharma reports on Feb 10, 2027, before the open (85 days away), and beat the EPS estimate in 8 of its last 8 reports.
Feb 10, 2027
Expected before the open, 85 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $1.32 est $1.27 | $773.0M est $758.9M | −0.4% |
| May 6, 2026 | $1.30 est $1.18 | $925.0M est $881.7M | −0.5% |
| Feb 11, 2026 | $1.46 est $1.29 | $874.0M est $807.0M | +1.3% |
| Nov 5, 2025 | $1.17 est $0.99 | $609.3M est $717.4M | +7.8% |
| Aug 6, 2025 | $1.14 est $1.03 | $578.7M est $673.0M | −2.4% |
| May 8, 2025 | $1.06 est $0.95 | $568.2M est $705.3M | +1.2% |
| Feb 11, 2025 | $1.15 est $1.05 | $594.0M est $687.1M | +2.0% |
| Nov 6, 2024 | $1.04 est $0.93 | $564.7M est $696.9M | −3.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Royalty Pharma is $72.00, +5.1% from the last close, from 6 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 6 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 5 | Citi | $78 | +13.8% |
| Nov 4 | J.P. Morgan | $74 | +8.0% |
| Oct 12 | Citi | $70 | +2.1% |
| Oct 9 | Bank of America Securities | $63 | −8.1% |
| Oct 7 | Morgan Stanley | $67 | −2.2% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 17, Royalty Pharma averaged −3.4% across the last 5 years, rising in 1 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.4% | 4 of 5 |
| Next 10 trading days | +1.1% | 4 of 5 |
| Next 15 trading days | −1.0% | 2 of 5 |
| Next 20 trading days | −3.4% | 1 of 5 |
| Next 30 trading days | −2.2% | 1 of 5 |
For scale, RPRX’s typical 20-trading-day move in either direction is about 3.9%.
Royalty Pharma’s market cap is $30.51B, with a P/E ratio of 45.3 and revenue of $2.62B over the last twelve months.
5 headlines about Royalty Pharma from the past week, newest first, each linking to the publisher.
Royalty Pharma’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 23.2% above |
| JNJJohnson & Johnson | Neutral | 3.6% above |
| ABBVAbbVie | Neutral | 23.4% above |
| MRKMerck | Neutral | 10.0% below |
| AZNAstraZeneca | Neutral | 34.5% below |
| PFEPfizer | Accumulation | 8.0% below |
A peer links to its own page where one exists.
Royalty Pharma’s market cap is $30.51B at the Nov 16, 2026 close of $68.53, with 445.3M shares outstanding. The shares trade on a P/E ratio of 45.3.
The consensus analyst 12-month price target for Royalty Pharma is $72.00, +5.1% from the last close. Of the 6 firms that rated the stock in the last 90 days, 6 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Royalty Pharma is overvalued: the Nov 16, 2026 close of $68.53 is 21.8% above Gekko Fair Value of $56.26. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Royalty Pharma is expected to report on Feb 10, 2027, before the market opens (85 days away). Analysts expect earnings of $1.53 per share on revenue of $960.7M. Royalty Pharma beat the earnings estimate in 8 of its last 8 reports, moving 2.4% on average across the report.
Royalty Pharma’s 52-week high is $70.37 and its 52-week low is $37.31; it closed at $68.53 on Nov 16, 2026, +72.5% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,476 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.